Related Experiment Video

Updated: Jan 30, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.4K

Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure

Alejandro Martin-Malo1, Gerrit Borchard2, Beat Flühmann3

  • 1Hospital Universitario Reina Sofía, Department of Nephrology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), University of Córdoba, Córdoba, Spain.

ESC Heart Failure
|January 30, 2019
PubMed

Insights

Iron deficiency is common in chronic heart failure (CHF). Intravenous iron therapy can correct this, but different iron products are not interchangeable without direct comparison studies in CHF patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Iron deficiency is a prevalent issue in chronic heart failure (CHF) patients, contributing to anemia.
  • Intravenous (i.v.) iron therapy is a recognized treatment for iron deficiency in CHF.
  • Current European Society of Cardiology guidelines recommend iron status screening and treatment with ferric carboxymaltose in CHF.

Purpose of the Study:

  • To review the characteristics and clinical implications of different intravenous iron products in chronic heart failure.
  • To assess the interchangeability of various i.v. iron therapies based on existing clinical and non-clinical data.
  • To provide guidance on the extrapolation of study results between different i.v. iron products in CHF patients.

Main Methods:

  • Review and synthesis of published clinical and non-clinical studies on i.v. iron products in CHF.
  • Analysis of the physico-chemical properties of i.v. iron complexes, focusing on the role of the carbohydrate ligand.
  • Evaluation of pharmacokinetic/pharmacodynamic profiles and immune system interactions of different i.v. iron formulations.

Main Results:

  • All i.v. iron complexes share a similar core structure but differ significantly due to their specific carbohydrate ligands.
  • These carbohydrate ligands influence critical properties like molecular weight, stability, and labile iron content, impacting metabolic fate and immune response.
  • Study results from one i.v. iron product cannot be assumed equivalent to others lacking comparable data in CHF.

Conclusions:

  • The carbohydrate moiety is a critical determinant of i.v. iron product behavior and clinical outcomes.
  • Extrapolation of efficacy and safety data between different i.v. iron products in CHF patients is not recommended without head-to-head studies.
  • Therapeutic substitution of ferric carboxymaltose with other i.v. iron products in vulnerable CHF populations requires robust evidence of equivalence.

Keywords:
Ferric carboxymaltoseHeart failureIntravenousIron deficiencyNanomedicinesParenteral

More Related Videos

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

5.6K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
894
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
865
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
329
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
305